ReShape unveils $6M offering, stock falls 50%

ReShape's gastric balloons (ReShape)

Shares in ReShape Lifesciences tumbled after the company disclosed a $6 million registered direct offering. The financing gives ReShape, formerly known as EnteroMedics, money to support the commercialization of its weight loss devices, but the move caused investors to buck.

San Clemente, California-based ReShape sells the FDA-approved ReShape balloon system and vBloc Therapy to help obese patients lose weight. The saline-filled silicone balloons sit in the stomach to decrease the space available for food and thereby help patients feel full sooner. VBloc has the same goal, but it seeks to achieve it by blocking hunger signals sent along the vagus nerve.

Penny stock ReShape closed out the third quarter with $23.4 million in cash and put together the direct offering to increase the funds it has available to support the commercialization of its products. The offering delivers that cash boost, but ReShape pulled it off by pricing its stock at $0.75 a pop, well below its closing price prior to news of the financing. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Investors responded by driving down the company’s stock price by more than 50%. The stock is now trading at $0.70 a share, just below the offering price. 

The steep decline continues the turbulent ride for ReShape and its investors, which went through a 1-for-70 reverse stock split when the company was known as EnteroMedics. Last year, EnteroMedics sought to improve its fortunes by acquiring ReShape for its balloon system and then adopting the name of the purchased business. 

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.